Pham Quang X sold $70K of CVKD
Pham Quang X (Chairman, CEO and Interim CFO) sold 18,124 shares of Cadrenal Therapeutics, Inc. (CVKD) at an average of $3.88 ($3.58–$4.12) across 3 trades over 2026-06-11 to 2026-06-15 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest concrete fact is the disclosed open-market sale of 18,124 shares by the CEO/Chairman/10% owner at a weighted average price of $3.8817, with a stated pre-arranged 10b5-1 plan.
Market read
This is a primary-source insider selling event; it can influence short-term sentiment but is less informative due to 10b5-1 pre-arrangement.
What to watch
Traders may also consider whether there were any concurrent insider buys, changes in total insider ownership, or subsequent filings after this sale window.
Background
The article is an SEC Form 4 insider transaction disclosure for Cadrenal Therapeutics, Inc.
Ticker impact
Cadrenal Therapeutics insider Pham Quang X (CEO/Chairman/10% owner) sold $70.4K of CVKD shares via a 10b5-1 plan during 6/11–6/15.
Likely limited near-term impact; any effect should fade unless follow-on selling or fundamentals change.
The filing is a primary-source insider transaction, but the article specifies it was executed under a pre-arranged Rule 10b5-1 plan, reducing signal strength.
Market effects
No sector-level read-through; this is company-specific insider activity.
None indicated.
None indicated.
Counterpoint
Because the sales were executed under a pre-arranged 10b5-1 plan, the disclosure may reflect scheduled liquidity rather than bearish expectations.
Key entities
- issuerCadrenal Therapeutics, Inc.
Company whose shares were sold by an insider; subject of the Form 4 disclosure.
- insiderPham Quang X
Chairman, CEO, Interim CFO, and 10% owner who sold shares under a Rule 10b5-1 plan.
